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Abstract
OBJECTIVES: Following mitral valve repair for Barlow’s disease, recurrent mitral regurgitation (MR) is believed to occur frequently and is
mainly attributed to disease progression.
METHODS: Between January 2000 and December 2015, 180 patients (40% women, mean age 58.7 ± 13.5 years) with Barlow’s disease
underwent mitral valve repair. To provide a longitudinal assessment of mitral valve repair durability, a multistate model for interval-
censored observations (4 states: 1, Grade 0/1+ MR; 2, Grade 2+ MR; 3, Grade 3+/4+ MR; 4, reintervention/death) was developed. The
mechanism of recurrent MR was assessed echocardiographically.
RESULTS: Early mortality was 1.7%. After hospital discharge, 6 late reinterventions were performed. With death as a competing risk, the
10-year overall reintervention-free survival and reintervention rates were 79.8% (95% confidence interval 72.7–87.6%) and 4.5% (95% con-
fidence interval 2.0–10.2%), respectively. Echocardiographic follow-up was available for 165 (93%) of hospital survivors with a total of 480
examinations. The incidence of both recurrent Grade 2+ and Grade 3+/4+ MR was relatively low up to 10 years after surgery. Grade 2+ MR
did not always progress to higher regurgitation grade during the follow-up period. Grade 3+/4+ regurgitation was highly associated with
valve-related morbidity and mortality. Recurrent MR (>_Grade 2+) was predominantly related to the technical aspects of valve repair.
CONCLUSIONS: Despite the complex valve abnormalities observed in patients with Barlow’s disease, mitral valve repair can be performed
with good early and late outcomes and low rates of recurrence of MR up to 10 years after surgery. Early and late valve repair durability is
good and remains stable over time, suggesting that underlying disease progression has limited clinical significance.
Keywords: Mitral valve • Mitral valve repair • Barlow’s disease
INTRODUCTION
Barlow’s disease presents the most severe form of degenerative
mitral valve disease and is characterized by severe annular, leaflet
and subvalvular abnormalities. Improved understanding of valve
dysfunction and growing surgical expertise nowadays allows for
restoration of mitral valve competency in the majority of these
patients [1, 2]. However, recurrent mitral regurgitation (MR) remains
a concern even in the hands of experienced surgeons [3, 4].
Surgical valve repair strategy in Barlow’s disease differs from
the repair strategy in other forms of degenerative disease as it
needs to take into account the profound annular abnormalities
seen in these patients [5–8]. Even when corrected for known sur-
gical risk factors for recurrent MR, Flameng et al. [3] have
previously demonstrated that recurrent MR occurs at a linearized
rate of 2.9% per year for patients with Barlow’s disease. The
authors proposed that Barlow’s disease carries an inherent ten-
dency to disease progression even after a successful valve repair.
Other authors have later reached similar conclusions [2]. On the
contrary, it has previously been proposed that valve degenera-
tion occurs as a consequence of abnormal mechanical stress that
will, in genetically predisposed individuals, result in the activation
of valve interstitial cells and extracellular matrix remodelling [9].
Mitral valve repair should therefore also aim to eliminate any
excessive stress to the mitral valve apparatus. Disease progression
after an initially successful valve repair is thus possibly inherent
to the technique of valve repair rather than the disease itself. To
provide further insight into the repaired valve performance, the
application of longitudinal data analysis rather than time-
to-event methods has been advised [10]. This could provide
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further understanding of the course of the disease following suc-
cessful valve repair.
The aim of this study was to explore the early and late patient-
and valve-related outcomes of mitral valve repair in patients with
Barlow’s disease. Moreover, we aim to gain in-depth information
on mitral valve repair performance by analysing echocardio-




Between January 2000 and December 2015, 684 consecutive
adult patients underwent surgical intervention for MR due to
degenerative mitral valve disease at our institution. Patients with
accompanying active mitral valve infective endocarditis were
excluded. Of the total patients, 185 (27%) patients showed both
echocardiographic and surgical characteristics of Barlow’s dis-
ease. These included excessive leaflet tissue, bileaflet myxoma-
tous degeneration and mitral annular disjunction [6, 11]. Mitral
valve repair was attempted in all cases and successfully per-
formed in 181 (98%) patients. Excluding 1 patient who under-
went valve repair with the edge-to-edge technique, 180 patients
who underwent valve repair present the final study cohort.
Study methods
Pre-, intra-, and postoperative data were collected from our
computerized patient registry. Follow-up clinical and echocardio-
graphic data were collected through clinical visits at our institu-
tion or affiliated clinics and hospitals and through patient
questionnaires. Our Institutional Medical Ethics Committee
approved this study, and written informed consent was obtained.
Patient follow-up was closed in February 2017. Details on patient
follow-up are provided in Supplementary Material A.
Surgical procedure
During the study period, a repair-all strategy was applied and even-
tual valve replacement was only performed in case of an unsatisfac-
tory intraoperative result of valve repair. Median sternotomy
(n = 157), partial sternotomy (n = 13) or lateral mini-thoracotomy
was performed (n = 10). Standard cannulation techniques with
central or peripheral cannulation (according to the surgical
approach utilized) and intermittent warm blood cardioplegia for
cardioprotection were used in all cases.
We have previously reported our surgical repair strategy in
patients with Barlow’s disease [7]. This includes discrimination
between true and functional leaflet prolapse that occurs in patients
with Barlow’s disease as a consequence of profound annular
motion abnormalities. In such cases, echocardiographic evidence
of anterior mitral valve leaflet (AMVL) prolapse in a combination
with annular displacement and abnormal annular motion suggests
that AMVL prolapse can be resolved by annular stabilization alone.
The final discrimination between true and functional leaflet pro-
lapse is made during surgical valve analysis.
Commissural prolapse was treated predominately by papillary
muscle head repositioning. To treat posterior mitral valve leaflet
(PMVL) prolapse and excessive tissue, quadrangular resection
with annular plication (earlier in our series) or leaflet sliding tech-
niques (later in our series) was used when excessive tissue in
height and width was present. Alternatively, a triangular resection
combined with shortening polytetrafluoroethylene neochords
were used to correct for excessive leaflet in width and height,
respectively. True AMVL prolapse was treated predominantly
with polytetrafluoroethylene neochords. Full, semi-rigid ring
annuloplasty was performed in all except 1 patient who under-
went a full, flexible ring implantation. Ring sizing was based on
the surface area of the AMVL.
Intraoperative and predischarge echocardiography were per-
formed by experienced echocardiographists to confirm the success
of valve repair. Oral anticoagulation with a target international nor-
malized ratio of 2.0–3.0 was continued for 3 months after surgery. In
the presence of other indications, oral anticoagulation was contin-
ued as indicated.
Study end-points
Postoperative mortality and morbidity end-points were defined
according to the joint Society of Thoracic Surgeons, American
Association for Thoracic Surgery and European Association for
Cardio-Thoracic Surgery Guidelines [10]. Early mortality was defined
as mortality within 30 days after the operation or during the index
hospitalization. The severity of MR was evaluated using a multipara-
metric integrative approach, including qualitative and quantitative
assessments as currently recommended [12]. The severity of MR
was graded on a 4-grade scale: 1+ (mild), 2+ (moderate), 3+ (mod-
erate-to-severe) and 4+ (severe). To explore the mechanism of
mitral valve repair failure, echocardiograms were re-evaluated by a
cardiologist experienced in cardiac echocardiography (N.A.M.).
Pseudoprolapse was defined as a condition in which the free edge
of one mitral valve leaflet was displaced above the free edge of the
opposing leaflet in systole without over-riding the plane of the
annulus. Early recurrent MR was arbitrarily defined as >_Grade 2+
MR observed within the first 2 years after the initial operation. Late
recurrent MR was defined as >_Grade 2+ MR observed later than
2 years after the initial operation.
Statistical analysis
Continuous data are presented as means ± standard deviation for
normally distributed data or median and interquartile range
(IQR) when non-normally distributed. Categorical data are pre-
sented as counts and percentages. The cumulative incidences of
reintervention and death were estimated using the Aalen–
Johansen estimator [13]. For the remaining analyses, a multistate
model for interval-censored observations was developed [14].
The follow-up for the multistate model was set at 3 months after
the operation. The following 4 states were defined: ‘Grade 0 or
1+ MR’, ‘Grade 2+ MR’, ‘Grade 3+ or 4+ MR’ and the terminal state
‘reintervention/death’ (Fig. 1). This type of multistate model is
designed for situations where patients can move back and forth
between states (i.e. echo grades) and where the times at which a
patient changes state (e.g. moves from Grade 2+ to Grade 3+) are
not exactly observed. The hazards of transitioning between the
states were taken to be constant, after tests for a change in haz-
ard at 1.5 or 2 years were not significant. In the unadjusted analy-
ses, none of the 7 hazards were assumed to be equal to each
other. For the adjusted analyses, 3 hazards were allowed: deterio-
ration (moving to a higher state), improvement (moving to a
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lower state) or reintervention/death (moving to the terminal
state). First, univariate analyses at the 15% level were performed.
Then, a multivariate model was made, in which covariates were
constrained to only have an effect on those hazards on which
they had a significant effect in the univariate analyses. The multi-
state models were estimated using the MSM package in R [15].
RESULTS
Baseline characteristics
The baseline characteristics of the whole study cohort are pre-
sented in Table 1. On admission, the majority of patients were
symptomatic and a history of atrial fibrillation was present in
more than one-third of patients. Left ventricular functional
impairment and left ventricular dilatation were present less often.
The majority of patients showed echocardiographic evidence of
bileaflet prolapse, and in a relatively high proportion of patients,
mitral annular calcification was seen. The majority of patients
underwent elective surgery.
Early results
The intraoperative details on mitral valve repair and concomitant
procedures performed are provided in Table 2. Early mortality
was 1.7% (3 patients, Table 3). The cause of death was multiorgan
failure in 2 patients and perioperative myocardial infarction in 1
patient. All of the deceased patients were symptomatic and had
a history of atrial fibrillation. No major postoperative complica-
tions occurred in most (81.7%) patients.
Postoperative resting mitral valve gradient was 3.26 ±
1.42 mmHg and was significantly lower in patients in whom no
annular plication was used (2.92 ± 1.22 and 3.93 ± 1.56, P < 0.001).
No significant systolic anterior motion was present in any of the
patients. In 2 (1.1%) patients, significant residual MR (>_Grade 2+)
was observed on predischarge echocardiography (Supplementary
Figure 1: Multistate model design. State ‘reintervention/death’ presents a ter-
minal state while transitions between other states are freely allowed. MR: mitral
regurgitation.
Table 1: Baseline characteristics
n = 180
Age, years 58.7 ± 13.5





Preoperative atrial fibrillation 66 (36.7)
Hypertension 58 (32.2)
Renal impairment
Moderate (CC 85–50 ml/min) 80 (44.4)
Severe (CC <50 ml/min) 5 (2.8)
Extracardiac arteriopathy 1 (0.6)
History of TIA or CVA 4 (2.2)
Chronic lung disease 11 (6.1)
Diabetes mellitus 2 (1.1)
Non-elective surgery setting 3 (1.7)
Critical preoperative state 1 (0.6)
Left ventricular ejection fraction
>60% 127 (70.6)
30–60% 53 (29.4)
Left ventricular end-systolic diameter >45 mm 12 (6.7)
Pulmonary hypertension (sPAP >50 mmHg) 7 (3.9)
Leaflet prolapse
None 4 (2.2)
Isolated anterior 5 (2.8)
Isolated posterior 24 (13.3)
Bileaflet 147 (81.7)
Mitral annular calcification 32 (17.8)
Data are presented as n (%).
CC: creatinine clearance; CVA: cerebrovascular accident; NYHA: New
York Heart Association; SD: standard deviation; sPAP: systolic pulmo-
nary artery pressure; TIA: transient ischaemic attack.
Table 2: Intraoperative details
n = 180
Mitral valve annulus
Annular plication 61 (33.9)
Decalcification 26 (14.4)
Annuloplasty ring size 36 (IQR 32–38)
Anterior mitral valve leaflet
Resection 3 (1.7)
Neochords 83 (46.1)
Chordal transfer 1 (0.6)
Chordal shortening 1 (0.6)
Posterior mitral valve leaflet
Resection 150 (83.3)
Sliding plasty 132 (73.3)
Neochords 55 (30.6)
Chordal transfer 2 (1.1)
Chordal shortening 1 (0.6)
Papillary muscle head repositioning 2 (1.1)
Identation closure 35 (19.4)
Commissures
Anterior commissure 26 (14.4)
Papillary muscle head repositioning 19 (10.6)
Commissuroplasty 6 (3.3)
Neochords 1 (0.6)
Posterior commissure 65 (36.1)
Papillary muscle head repositioning 57 (31.7)
Commissuroplasty 7 (3.9)
Neochords 1 (0.6)
Aortic cross-clamp time (min) 153 (IQR 137–200)
Cardiopulmonary bypass time (min) 203 (IQR 174–250)
Second pump run 14 (7.8)
Concomitant procedures
Tricuspid valve repair 95 (52.8)
Radiofrequency ablation 56 (31.1)
Coronary artery bypass grafting 16 (8.9)
Aortic valve intervention 5 (2.8)
Thoracic aorta replacement 2 (1.1)
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Material, Fig. S1) and both underwent early reoperation. One
patient showed residual AMVL prolapse and underwent reopera-
tion on postoperative day 8. Valve replacement was performed as
a durable repair was considered unlikely because of a severely
degenerated and malformed AMVL. The second patient showed
residual PMVL prolapse and underwent mitral valve re-repair on
postoperative day 8.
Late clinical outcome
There were 22 late deaths. The cause of death was valve related
in 10 (intracranial bleeding in 2; death following mitral valve
reoperation in 1; end-stage heart failure with recurrent MR in 1;
sudden, unexplained death in 6) and cardiac related but not
valve related in 3 (myocardial infarction in 1; type A aortic dissec-
tion several years after the initial procedure in 1; end-stage heart
failure in 1) patients. The cause of death was not cardiac related
in 9 patients.
Following hospital discharge, 6 late reinterventions were per-
formed. The cause of reintervention was prosthetic valve endocar-
ditis in 1 patient, suture line defect of the PMVL in 1 patient,
recurrent MR in 3 patients and secondary MR in 1 patient. Taking
all-cause death and mitral valve reintervention as competing risks,
the 5- and 10-year cumulative incidence of reintervention-free
survival were 89.5% [95% confidence interval (CI) 84.8–94.4%] and
79.8% (95% CI 72.7–87.6%), respectively (Fig. 2).
Eleven patients experienced a thromboembolic event. Five of
these were cerebrovascular accidents and 6 were cerebral transi-
ent ischaemic attacks. No events were fatal. Six patients experi-
enced serious haemorrhagic complications resulting in death in 2
(intracranial bleeding in both cases) patients. There was one epi-
sode of infective endocarditis (occurring 1 month after the initial
intervention), resulting in a reoperation.
Late echocardiographic outcome
Figure 3 shows the time-related changes in the percentage of
patients in various states over time. As expected, patients alive and
free from reintervention showed good repair durability up to
10 years after the initial operation. Interestingly, Grade 2+ MR did
not always progress with time but remained stable or even
regressed with time (upon any of the following echocardiographic
measurements; Supplementary Material, Fig. S2). When stratifying
patients based on the observed severity of MR, the reintervention-
free survival probability was best for patients without any
significant MR (Supplementary Material, Fig. S2). All transitions
from state 1 to state 4 were deaths. All transitions from state 3 to
state 4 were valve-related events: 5 were reinterventions and 1 was
valve-related death (end-stage heart failure with recurrent MR).
Multivariate analysis showed only male gender as a statistically
significant protective factor (hazard ratio 0.32, 85% CI 0.11–0.91)
against repaired valve functional deterioration (Supplementary
Material, Table S1). In particular, posterior mitral valve leaflet
resection (no leaflet resection was performed in a relatively small
number of patients in whom only excessive tissue in height was
present and treated by implanting shortening neochords) or the
presence of annular calcification did not affect repaired valve
performance. Multivariate analysis demonstrated only advanced
Figure 2: Competing risk of outcomes. Time-related parametric estimates with
95% confidence intervals (dashed lines) are presented for the following mutu-
ally exclusive categories: death (red), reintervention (blue) and patients alive
without reintervention (green).
Figure 3: Multistate model demonstrating the time from the initial operation-
dependent percentage of patients in each of the predefined states. MR: mitral
regurgitation.
Table 3: Postoperative complications
n = 180
Early mortality 3 (1.7)
Sternal wound infection 0 (0)
Prolonged intubation (>24 h) 20 (11.1)
Renal failure 5 (2.8)
Permanent stroke 2 (1.1)
Early reoperation 19 (10.5)
Re-exploration for bleeding and/or cardiac tamponade 17 (9.4)
Early valve reoperation 2 (1.1)
Data are presented as n (%).
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patient age (>60 years; HR 3.21, 85% CI 1.16–8.85) as a significant
risk factor for transition to state 4.
Mechanism of recurrent mitral regurgitation
Echocardiographic assessment revealed that recurrent MR was
most commonly related to the technical aspects of valve repair
(Table 4). Early recurrent MR (within the first 2 years after sur-
gery) was seen in 11 patients. This was caused by residual pro-
lapse/billowing and suture line defect in 5 patients and 1 patient,
respectively. Leaflet restriction—usually combined with pseudo-
prolapse of the opposite mitral valve leaflet—was the cause in 4
patients, while the cause of recurrent MR was not clear in 1
patient.
Late recurrent MR was seen in 9 patients. A combination of
leaflet restriction with or without pseudoprolapse of the opposite
leaflet presented the most common cause of repair failure. In 1
patient, valve analysis upon reoperation revealed that leaflet
restriction was likely caused by the repositioned papillary muscle
head. Recurrent prolapse (evidence of chordae rupture was also
seen on echocardiography) as the sole cause of repair failure was
seen in only 1 patient. Of notice, leaflet thickening as the cause
of recurrent MR was seen in 1 patient only.
DISCUSSION
Our study showed that a systematic valve repair strategy in
Barlow’s disease, utilizing a combination of leaflet resection tech-
niques, subvalvular apparatus manipulation, neochords implanta-
tion and annular stabilization, is highly reproducible and will
allow valve repair to be performed in nearly all patients.
Recurrent MR—occurring early or late—was most commonly
related to the technical aspects of valve repair and not disease
progression. Furthermore, once occurring, Grade 2+ MR did not
always progress with time during the follow-up period.
We adhere to an early surgery approach in all patients with
degenerative mitral valve disease and advise surgery to asympto-
matic patients with severe MR, regardless of the expected repair
complexity. This is in line with the recommendations of the
American Heart Association/American College of Cardiology on
the management of valvular heart disease [16]. On the other
hand, the recently updated guidelines from the European Society
Table 4: The mechanism of recurrent MR in patients in whom >_Grade 2+ MR was seen at any point during the follow-up period
Case Year of
surgery
AMVL PMVL Time to first
observation
Last observation Reintervention Time to
reintervention
(years)
MR grade Years MR grade Years
1 2001 Prolapse 2+ 0.5 4+ 1.1 Yes (MVR) 1.5










3 2002 Suture line defect 4+ 0.1 4+ 0.1 Yes (re-repair) 0.6
4 2004 Not clear Not clear 2+ 2.0 2+ 11.0 No
5 2004 Residual billowing
(insufficient leaf-
let coaptation)
2+ 1.8 2+ 10.7 No
6 2005 Restriction Pseudoprolapse 4+ 1.0 4+ 1.0 Yes (MVR) 1.4
7 2009 Restriction 3+ 1.2 3+ 1.2 No








3+ 1.0 3+ 2.8 No
11 2014 Prolapse 2+ 1.1 2+ 2.5 No
12 2003 Thickened leaflet Restriction+thickened
leaflet
2+ 8.5 2+ 12.5 No
13 2004 Unknown Unknown 2+ 7.3 2+ 8.8 No
14 2004 Restriction Relatively short but
mobile (loss of
coaptation)
2+ 8.9 3+ 12.6 No




2+ 3.5 4+ 7.0 Yes (MVR) 7.0
16 2006 Pseudoprolapse 2+ 5.8 2+ 5.8 No
17 2007 Restriction Decreased mobility 2+ 6.1 2+ 8.7 No
18 2008 Prolapse 3+ 4.7 4+ 5.7 No
19 2008 Restriction Pseudoprolapse 3+ 8.1 3+ 8.8 No
20 2012 Pseudoprolapse Restriction 2+ 3.1 2+ 3.1 No
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of Cardiology/European Association of Cardio-Thoracic Surgery
advise considering surgery in asymptomatic patients only when
favourable anatomy (flail leaflet) or significant left atrial dilatation
is present [17]. The high proportion of patients in whom success-
ful valve repair with a documented good result was feasible is
believed to support an early surgical approach even in patients
with complex valve pathology. It is, however, imperative that
such patients are referred to centres with sufficient experience in
reconstructive valve surgery.
The majority of patients underwent valve repair through stand-
ard full sternotomy with—especially later in our series—limited
midline skin incision (approximately 10–15 cm in length).
Previous studies have demonstrated favourable results of the
minithoracotomy approach to valve repair in patients with
Barlow’s disease [18, 19]. However, this includes significant modi-
fications of the mitral valve repair technique when compared
with our technique. We remain reluctant to utilize the edge-to-
edge repair technique in patients with degenerative mitral valve
disease because this technique has been demonstrated to have a
profound effect on diastolic transvalvular mitral valve gradients
[20]. We have to acknowledge, however, that patients with
Barlow’s disease usually present with large valve orifice areas and
large annuloplasty rings-making functional mitral valve stenosis
unlikely to occur regardless of the repair technique utilized- are
utilized to complement valve repair. In our opinion, the decision
on the type of approach should be based on the decision of the
informed patient and projected repair complexity. Surgical
approach should not determine the strategy of mitral valve
repair.
Interestingly, female gender had a negative effect on valve
repair durability. Our study is not the first to report such find-
ings and further studies are needed to explore the underlying
causes of such observations [21]. Our results further suggest that
even Grade 2+ MR after mitral valve repair might remain stable
for years. In line with this observation, the time-related proba-
bility of death or reintervention appeared only moderately
higher once Grade 2+ MR was observed. There are several pos-
sible explanations for these findings. Such observations can be
partially explained by the fact that grading of the severity of MR
is based on arbitrarily defined grades while the amount of
regurgitant flow presents a continuous biological parameter.
The severity of MR is dependent on various factors that can
present an extrinsic and reversible cause of repaired valve func-
tion deterioration [10]. On the other hand, it should be
acknowledged that the follow-up time in our patients was lim-
ited. In these patients, the severity of MR might progress in the
future and necessitate reoperation. Taking this into considera-
tion, close follow-up should be advised in all patients, while fur-
ther research is needed to assess the clinical significance of our
findings. On the other hand, the occurrence of >_Grade 3+ MR
was clearly related to valve-related morbidity and mortality.
Importantly, the underlying mechanism needs to be taken into
account when assessing the expected clinical significance and
prognosis of ‘recurrent MR’. Our observations should therefore
be interpreted with caution.
In a previous study on 348 patients (including 83 patients with
Barlow’s disease) who underwent successful valve repair for
degenerative mitral valve disease, Flameng et al. [3] have shown
that recurrent MR (>2/4 MR) occurs most commonly because of
recurrent leaflet prolapse or leaflet thickening. They hypothesized
that even after a sound surgical repair, disease progression
presents an inherent characteristic of Barlow’s disease. We argue
that valve repair that successfully resolves any excessive stress on
the mitral valve leaflets and subvalvular apparatus should provide
good repair durability even in cases of Barlow’s disease. To assure
a stable, durable valve repair, a large surface area of leaflet coap-
tation without any residual malaposition of the mitral valve leaf-
lets—that would result in undesirable tension to the leaflets and
chordae tendineae—needs to be achieved. Annular stabilization is
of utmost importance in these patients as annular abnormalities
(diminished annular saddle shape and abnormal motion)
increase the strain exerted to the mitral valve leaflets. Ring annu-
loplasty with a suitable annuloplasty device that mimics the nor-
mal systolic annular saddle shape can resolve these issues. This is
supported by the fact that leaflet thickening was an uncommon
observation in our experience, despite the fact that this has been
reported to present the most common mechanism of repair fail-
ure in patients with degenerative disease [22]. The very low rate
of disease progression as a cause of failure underlines that these
operations stabilize the disease and could therefore be advised
even to asymptomatic patients.
In our experience, the most common mechanism of recurrent
MR was leaflet restriction, usually combined with pseudopro-
lapse of the opposite leaflet. Hypothetically, this could present a
consequence of leaflet resection. Contrary to this speculation,
leaflet resection did not predict worsening of repaired valve
function on multivariate analysis. We speculate that resection
will not per se induce clinically significant leaflet restriction.
However, ‘excessive’ leaflet resection might well induce leaflet
restriction and eventually result in pseudoprolapse of the oppo-
site leaflet. Loss of sufficient leaflet coaptation height will induce
excessive residual strain on the mitral valve leaflet(s), indicating
instability of valve repair in the long term. This would explain
the similarity in the mechanism of early and late recurrent MR
seen in our experience. It also suggests that even late recurrent
MR can be directly related to the technical aspects of valve
repair. Furthermore, insufficient height of leaflet coaptation
might result from other technical aspects of valve repair (inad-
equate ring sizing) and might in patients with Barlow’s disease
result from the inability to prevent abnormal annular motion. In
our opinion, this provides a possible argument for the utiliza-
tion of semi-rigid instead of flexible annuloplasty devices in
these patients. However, the effect of various annuloplasty devi-
ces on annular motion in patients with Barlow’s disease needs
to be studied further.
Limitations
Our study is retrospective in nature and therefore subject to the
inherent weaknesses of a retrospective analysis. The valve repair
technique has somehow evolved throughout the study period
(i.e. abandonment of the annular plication technique) and might
have affected the results. We reason that this could have only a
limited effect on repair durability. Furthermore, our results in
terms of repaired valve performance are based on our experi-
ence only and the observations might not be applicable to other
techniques of valve repair. Finally, MR severity was—based on the
accepted recommendations—scored on a graded scale. Such sim-
plification inevitably results in a loss of possibly relevant informa-
tion regarding repaired valve durability. However, analysing MR
severity on a continuous scale would be statistically very complex
to conduct and interpret.
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CONCLUSION
Despite the complex valve abnormalities observed in patients
with Barlow’s disease, mitral valve repair can be safely performed
with good early and late outcomes. Early surgical intervention
seems to be justified, despite the complexity of valvular abnor-
malities normally observed. Early repair failure is largely related
to the technical aspects of valve repair. Late deterioration of
repaired valve function occurs infrequently and also appears
inherent to the surgical technique, suggesting that underlying dis-
ease progression has limited clinical significance.
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